Phase 3
Completed N=30
Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes
Xerophthalmia · Blepharitis
Source: ClinicalTrials.gov NCT00796926 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Aug 2011
Primary outcomePrimary: Visual Analog Score (VAS) — 21.55; 27.27 scores on a scale — p=>0.05
Summary
Systane Ultra is at least as efficacious and safe as Refresh Tears in Asian people with Dry Eyes
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Analog Score (VAS) |
21.55; 27.27 | >0.05 |
| SECONDARY Corneal Fluorescein Staining Score |
— | — |
| SECONDARY Tear Break Up Time (TBUT) |
— | — |
| SECONDARY Schirmer I Reading |
— | — |
| SECONDARY Meibography Grading |
— | — |
| SECONDARY Tear Osmolarity |
— | — |
| SECONDARY Superior and Inferior Tear Meniscus Height |
— | — |
Eligibility Criteria
Inclusion Criteria
- Subject age is between 40 and 65 years old.
- Corneal fluorescein staining present in at least one/five sectors of at least one cornea
- At least one question out of 6 questions on dry eye symptom present often or all the time.
based on the Salisbury Eye study by Oliver Schein et al. (Does your eye feel dry, gritty, red, watery, crusted, stuck in the morning?) Please see appendix 1.
- At least one of the following: TBUT <= 5 s or Schirmer I less than 8 mm in at least one eye
- Yamaguchi score 2 in at least one sector of one of 4 lids (slight advancement of Marx's line in line with Meibomian orifice)
- Not using non-lubricant ophthalmic drops within the last 30 days and able to abstain from non-trial topical eye medications for 6 weeks.
- Use of lubricants during the week before recruitment (ranging from 3 times in the week to less than 6 times a day every day).
- Able to use saline eyedrops during the 7 day 'washout' evaluative phase, between 3 times over week to less than 6 times a day in all days.
Exclusion Criteria
- Known history of thyroid disorders (diagnosed by physician).
- Known history of Sjogren syndrome or rheumatoid arthritis (diagnosed by physician).
- No ocular surgery within 6 months and LASIK within 1 year.
- Any intake of central nervous system and hormonal drugs within last 30 days and inability to withhold such drugs for at least 6 weeks.
- Ocular surface diseases such as pterygium, or obvious lid/orbital disease with lagophthalmos.
- Anticipated necessity to wear contact lens in the duration of the study.
- Not living in the same household as another participant of the study.
- Any other specified reason as determined by clinical investigator.
Data sourced from ClinicalTrials.gov (NCT00796926). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.